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T-cell tolerance to self-antigens is established in the thymus through the recognition by
developing thymocytes of self-peptide-MHC complexes and induced and maintained in
the periphery. Efficient negative selection of auto-reactive T cells in the thymus is depen-
dent on the in situ expression of both ubiquitous and tissue-restricted self-antigens and
on the presentation of derived peptides. Weak or inadequate intrathymic expression of
self-antigens increases the risk to generate an autoimmune-proneT-cell repertoire. Indeed,
even small changes of self-antigen expression in the thymus affect negative selection and
increase the predisposition to autoimmunity. Together with other mechanisms, tolerance
is maintained in the peripheral lymphoid organs via the recognition by mature T cells of a
similar set of self-peptides in homeostatic conditions. However, non-lymphoid peripheral
tissue, where organ-specific autoimmunity takes place, often have differential functional
processes that may lead to the generation of epitopes that are absent or non-presented in
the thymus.These putative differences between peptides presented by MHC molecules in
the thymus and in peripheral tissues might be a major key to the initiation and maintenance
of autoimmune conditions.
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PEPTIDE REPERTOIRE IN THYMUS
Differences between the peptide repertoires associated to MHC-
II molecules expressed by antigen presenting cells (APC) in the
thymus and in the periphery have been long proposed, but are
yet to be demonstrated (1). Such differences were expected after
the characterization of the different thymus APCs, some of which
have unique properties of their antigen processing machinery,
compared to peripheral APCs (2, 3). The earliest analysis of the
MHC-associated peptide repertoires in the thymus and spleen was
done in the mouse in the 90s (4), showing similar repertoires, but
the technological limitations of the time failed to provide a suffi-
cient number of peptides. The current technology and computer
tools have allowed better yields, providing a broader view of the
in situ presented peptides and in-depth study of the character-
istics and general composition of the MHC-associated peptide
repertories.
We have recently described the peptides presented by HLA-DR
molecules derived from pediatric thymus samples in homeosta-
tic conditions, that included the peptides presented by all thymus
APCs (5). As expected, the total expression of HLA-DR was at
least three times higher in the medulla than in the cortex region
(6). In this context, a major fraction of the described repertoire
would be medulla-derived and might thus represent the most
abundant peptides presented in thymus during negative selection.
Whether medullar or cortical, our data showed a thymus reper-
toire composed of a diverse number of peptides derived from a
wide range of proteins, i.e., not a highly redundant repertoire.
Proteins involved in most frequent functional events occurring in
the thymus, i.e., apoptosis and antigen processing, were major
providers of peptides for their presentation by HLA-DR. The
apoptosis-related peptides may come from the uptake of apop-
totic cells (mostly thymocytes) by APCs (7, 8) or directly from
the AutoImmune REgulator (AIRE)-induced mTEC apoptosis (9–
11). The remaining source proteins were of high diverse origin,
including nuclear and cytosolic proteins, conventionally consid-
ered as belonging to the Class I – endogenous pathway. Most
were conventional size MHC-II peptides from proteins derived
from membrane-rich compartments. Many were grouped into
nested sets and most represented a single region of the parental
protein at the expense of the rest of the sequence. Thus, these
data reveal that tolerance against a protein is usually developed
against a specific region, rather than to many epitopes of the
protein.
In a nearly simultaneous paper, Adamopoulou et al. (12)
reported the analysis of the thymus MHC-I and -II-associated
peptidome. This work analyzed DC and DC-depleted APCs from
the thymus separately, whereas our study included the peptides
presented by all thymus APCs, preferentially medullary APCs. The
results by Adamopoulou et al. essentially agree with our data, con-
firming a large number of source proteins of diverse origin and a
clear “cross-talk” between the MHC-I and -MHC-II pathways of
antigen processing. Recent results from our group on the MHC-I-
associated thymus peptidoma (13) show similar results including
the presentation of 20% peptides derived from proteins processed
by the exogenous pathway. Thus, the“non-conventional”pathways
of MHC-I and -II processing, i.e., cross-presentation of exoge-
nous antigens by MHC-I and autophagy and uptake of apoptosis
material for the presentation of cytosolic proteins by MHC-II, are
efficiently acting in the thymus. It remains to be analyzed which
of the thymus APCs are more involved in these pathways.
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In addition to HLA-DR, HLA-DM expression is also weaker in
the thymus cortex than in the medulla (6). HLA-DM is needed
for the high-stability binding of peptides to HLA-DR. HLA-DM
forms stable complexes with DR molecules following CLIP disso-
ciation at low pH and allows the formation of stable peptide-
MHC (pMHC) complexes (14, 15). Thus, peptides presented
in the medulla should be high-stability peptides forming stable
complexes (16). We observed that most HLA-DR ligands iden-
tified ex vivo from the thymus showed high predicted affinity
for one or both of the expressed HLA-DR alleles (5). In addi-
tion, the 12 allele-assigned peptides in the Adamopolou report (6
DRB1*03, 6 DRB1*04) were also high binders when analyzed by
the panMHC-II prediction software (17) (J. A. Collado, data not
shown).
The thymus can generate a large variety of MHC ligands for
display through activities like highly activated thymocyte prolifer-
ation and apoptosis, constitutive levels of autophagy by TECs (18,
19), antigen exchange between mTEC and DCs (20) or expression
of tissue-restricted antigens (TRA), by mTEC (21). The resulting
peptides will necessarily compete for de novo synthesized MHC-II
molecules. This constant competition should presumably favor the
presentation of the highest affinity ligands, displacing those pep-
tides with lower affinities for the binding groove. High-stability
peptides form long-life pMHC complexes at the APC surface,
increasing the possibility of recognition by self-reacting CD4+ thy-
mocytes and improving negative selection efficiency. In contrast,
low-stability complexes are short-lived, so they may be ignored or
only be recognized by a small number of thymocytes, increasing
the probability of escaping selection.
MHC-II PEPTIDE REPERTOIRE IN AUTOIMMUNITY
Secondary lymphoid organs are essential for the maintenance
of tolerance so MHC molecules should present much the same
peptides as those presented in thymus. Our analysis of a spleen
HLA-DR repertoire showed many common peptides with an HLA-
DR-matched thymus, and with slight differences related to the
spleen function such as a large number of peptides from blood
proteins (Collado et al., unpublished). However, few studies are
available concerning the peptide repertoires associated to MHC-II
in healthy lymphoid tissue (4, 22).
In contrast, there are more data describing the MHC-II pep-
tidome from non-lymphoid peripheral tissues, affected by autoim-
munity (23–25) or cancer (26). These were composed of pep-
tides that reflected the characteristic protein composition of each
organ. Albeit most peptides were from ubiquitous proteins, there
were sequences derived from tissue-restricted proteins potentially
related to the disease. We were the first to demonstrate the in vivo
presentation of thyroglobulin (Tg) peptides by HLA-DR in thyroid
glands affected by Graves’ disease (23). In later reports, peptides
from myelin basic protein (MBP) and other autoantigens were
identified in central nervous system (CNS) samples from mul-
tiple sclerosis (MS) patients (24), and peptides from collagen,
vimentin, and others were detected in synovial samples from
rheumatoid arthritis (RA) patients (25). Thus, tissue-expressed
MHC-II molecules displayed autologous peptides, including some
from known autoantigens. These proteins are abundant in these
tissues, and there should be enough specific-pMHC complexes
in situ to stimulate potential auto-reactive T cells. In our study,
we identified eight peptides from different regions of Tg, a major
component of the thyroid colloid and a common autoantigen in
autoimmune thyroid diseases (27). Similarly, up to six different
MHC-II-associated MBP peptides were identified from human
MS patients’ CNS (24) and several peptides from collagen in RA
patients (25). In contrast, the peptides identified in the thymus
in homeostatic conditions mostly came from one single region of
each protein. This suggests that a wide range of peptides derived
from the same protein may be generated and presented in the
autoimmune target tissue, whereas efficient tolerization in the thy-
mus may be only directed against the dominant epitope or epitopes
of each protein.
Furthermore, when we analyzed the potential affinity of pep-
tides from autoimmune thyroids, only one third of the sequences
corresponded to peptides with predicted high affinity for HLA-
DR (5). Only one out of the eight Tg sequences identified was
assigned to any HLA-DR allele, i.e., Tg2098, an immunodominant
Tg peptide (23, 28, 29). The remaining peptides were low-affinity
HLA-DR ligands, both according to predicted and experimental
binding data (5, 23). A prediction analysis of the affinity of CNS
peptides from MS patients (24) again showed less than 20% of
the peptides with high affinity and around 65% low-affinity pep-
tides (J. A. Collado, data not shown). So, contrary to thymus,
where low-affinity peptides appeared to be relatively unavailable
for presentation by HLA-DR, these peptides were abundant in the
affected tissue.
Thus, there are differences between the repertoires in thymus
and autoimmune-affected tissue: (i) no apparent immunodomi-
nance of any particular region of each protein, contrary to that
observed in thymus and (ii) low affinity of many autoantigenic
peptides generated in the peripheral tissue for the MHC-II mol-
ecules. Some of these peptides, able to bind MHC with lower
affinity, would be good candidate targets of the autoimmune
response.
MECHANISMS GENERATING REPERTOIRE DIFFERENCES
Specific cellular processes in peripheral tissues may modify the
outcome of antigen processing and presentation in situ. This can
favor the generation of peptides that would have been ignored
or not generated in the thymus. Several mechanisms may be
involved:
Tissue-specific proteolytic machinery affecting proteins before
uptake by APCs.
High concentration of tissue-specific antigens in the target
tissues.
Post-translational modifications of proteins in the tissues.
Expression of HLA-DR and DM in autoimmunity affected tissue.
T cells exclusive for tissue-derived peptides.
PROTEOLYSIS
Normal turn-over of tissue-specific proteins, cell death, extra-
cellular processing, together and different tissue proteases may
provide a source of peptides that will not be found in thy-
mus. In the thymus, lysosomal proteases and enzymes involved
in antigen presentation are diverse cathepsins (Cat), asparagine
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endopeptidase (AEP), and Gamma-interferon-inducible lysoso-
mal thiol reductase (GILT). Detailed cathepsin expression by each
particular cell subset of the human thymus has been recently
reported (2). Cat V is expressed only in the cortex while Cat
L is expressed by few cells distributed throughout the thymus
(30). cTEC and mTEC express all the studied cathepsins (B, D,
H, S, and X) and GILT. Mature DCs expressed the highest lev-
els of those cathepsins (especially Cat S). However thymus DCs
did no express Cat G in contrast to peripheral blood DCs (31).
The importance of cathepsins in tolerance is evidenced when
autoantigen processing is studied. Cat S processes MBP in thymus
DCs generating an immunodominant epitope that is destroyed
by Cat G in peripheral blood DCs. Cat S cleavage of proinsulin
can also destroy insulin T-cell epitopes (2). Moreover, NOD mice
deficient in Cat B, S, or L are protected from type I diabetes
development (32).
Besides the different cathepsins expressed by tissue APCs, extra-
cellular matrix remodeling or partial degradation of stored pro-
teins in the tissue milieu are another source of neo-epitopes. The
cleavage of Tg in the thyroid is a good example. Tg is produced by
thyroid follicular cells (TFC) and secreted into the colloid. Solubi-
lization and pre-cleavage of Tg are necessary prior to endocytosis
by TFC to generate T3 and T4 hormones. Cat B, L, S, K present
both in colloid and in the TFC’s endocytic vesicles cleave Tg at
different pH (neutral and acid pH, respectively) (33), giving a
different pattern of cleavage in each condition. Moreover, over-
expression of cathepsin B in the thyroid has also been reported
in autoimmune thyroid diseases (34). Similar extracellular matrix
remodeling occurs in other autoimmune diseases, such as RA,
where Cat S, K, B, and L are secreted to synovial fluid and tissue
(35, 36). Thus, the differential processing by APCs may be rele-
vant when comparing thymus and autoimmune peripheral tissue.
A wide range of different peptides can be generated in the affected
tissue, leading to the activation of auto-reactive T cells that were
not negatively selected, causing and maintaining the autoimmune
process.
DIFFERENTIAL DOSE OF ANTIGEN IN PERIPHERAL TISSUE VS. THYMUS
The expression of TRAs in the thymus is temporally regulated
and is weaker than in the corresponding peripheral tissue (37).
Major components of specific organs, such as insulin in the pan-
creatic islets or Tg in the thyroid gland, are expressed at low
levels in the thymus by a very small subset of HLA-DR+AIRE+
mTECs (38, 39). This suggests that to generate tolerance, a
small number of TRA peptides should be sufficient. However,
quantitative and qualitative variability of the presented peptides
may influence the number of auto-reactive T cells that exit the
thymus. In humans, the T1D-associated IDDM2 susceptibility
locus of the insulin gene (INS) contains variable number of
tandem repeat (VNTR) polymorphisms upstream to the INS
promoter. The length of these repeats is directly involved in
the control of the expression levels of insulin mRNA in the
thymus (40). A polymorphism of the thyroid stimulating hor-
mone receptor (TSHR) gene, with susceptible and protective
alleles corresponding to low and high expression of the gene
in the thymus and the target organ has also been described
(41). In a mouse model of thyroid autoimmunity, transgenic
BALB/c mice were generated with the human TSHR A-subunit
targeted to the thyroid and thymus. Two types of mice were
obtained, low and high TSHR expressors. When these mice were
immunized with a human TSHR construct and Treg cells were
depleted, the low-expressors suffered the disease (thyroid infil-
tration and damage) while the high expressors remained toler-
ant. Presumably, THSR peptides presented in the high expres-
sors’ thymus were enough to induce tolerance to all possible
epitopes, whereas low-expressors presented insufficient TSHR
peptides or presented them with low efficiency. These peptides
would be presented in periphery and responsible for the in situ
reactivity (42).
Therefore, peptides from all relevant antigens in the body
should be present in the thymus at an adequate concentration
to prevent autoimmunity. No data are as yet available of DR-
associated peptides from TRAs presented in the thymus, although
peptides from non-organ-specific proteins that are potential tar-
gets of autoimmune disease have been described (12) and we have
some data suggesting the presence of TRA-specific peptides in
thymus samples (Alvarez and Collado, unpublished data).
POST-TRANSLATIONAL MODIFICATIONS IN THE TISSUE
Other local events likely involved in the development of autoim-
munity are post-translational modifications (PTMs) common in
most mammalian proteins that allow the generation of neo-self
epitopes (43, 44). PTMs can occur spontaneously or arise by
enzymatic modification, altering the protein structure, and bio-
logical functions. Modifications of the proteolytic degradation can
also occur. PTMs that generate neo-self-peptides include enzyme-
dependent glycosylation (45), deamidation (46), citrullination
(47, 48), iodination (49), phosphorylation (50), methylation (51),
or chemical modifications such as disulfide bridge formation,
oxidative modification or nitration, and many others (52).
Many of these PTMs have been associated with one or more
autoimmune processes (53). One of the best studied PTM is citrul-
lination, the substitution of arginine by citrulline. Citrullination
increases the sensitivity of MBP to cleavage by cathepsin D, allow-
ing epitope destruction or neo-epitope generation (54–56). In
RA, citrullination may play a role in T-cell autoreactivity. RA-
associated HLA-DR molecules share a consensus sequence in the
peptide binding groove, named the “shared epitope” (SE) (57),
that contains a positively charged P4 peptide binding pocket. Cit-
rullination will remove a positively charged Arg residue from any
peptide, enhancing its ability to bind to SE-MHC-II molecules.
In a mouse model, the substitution of Arg by Cit in a candidate
vimentin peptide efficiently immunized DRB1*0401 transgenic
mice, whereas the original peptide did not. This analog showed
markedly enhanced binding to SE-HLA alleles, but not to other
alleles (52).
Thyroglobulin is extensively modified by iodination and other
post-translational events in the thyroid colloid. Iodinated Tg
epitopes are highly immunogenic and can trigger thyroid auto-
reactive T cells (49, 58). Other examples include the inhibition
of the generation of the 85–99 dominant epitope of MBP by
processing enzyme AEP in the thymus, thus limiting the recog-
nition of this epitope by thymocytes. AEP is not highly expressed
in CNS (59).
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FIGURE 1 |Thymus and peripheral tissue mechanisms involved in
antigen processing. (A) In thymus, tissue-restricted antigens (TRAs) are
expressed by medullary epithelial cells (mTECs) for negative selection.
Secretory TRAs are processed by self-proteases and peptides (orange
squares and red triangles) are loaded onto MHC-II molecules once exocytic
vesicles reach the MIIC compartment. Peptide exchange is mediated by
HLA-DM. Macroautophagy permits the access of cytosolic TRAs and other
proteins into the MIIC compartment so their processing and presentation via
MHC-II can take place. Besides their own proteome, thymus dendritic cells
(DC) are expected to present antigens via the uptake of apoptotic thymocytes
and mTECs, exosomes delivered by mTECs and other extracellular material.
Thymus-specific and conventional proteases generate high affinity peptides
from a wide range of self-proteins, thus favoring their presentation in
competition with low-affinity peptides. (B) In peripheral tissues, specific
proteases may be essential for peptide generation. A protein can generate
peptides for MHC-II in the secretory pathway. Tissue-specific
post-translational modifications may result in modified antigenic peptides
(orange squares from thymus are represented as green squares in periphery)
or even prevent the generation of some peptides. Once in the extracellular
environment, proteases could partially degrade the protein into smaller
fragments (yellow circles) that would be potential binders for MHC-II
molecules. In some cases protein storage outside the cells (e.g.,
thyroglobulin in thyroid colloid) is followed by protein turn-over into the cells.
Proteins or their cleavage products contained in endosomes can be
processed again in the MIIC compartment to generate MHC-II ligands. During
inflammation, infiltrating DCs can uptake the antigenic proteins or their
fragments for processing with their specific proteases. They can also
phagocyte apoptotic epithelial cells. Compared with thymus, events in
periphery may result in a set of presented peptides that were not used in
negative selection. Lack of competition with high affinity peptides and low or
absent expression of HLA-DM may result in the presentation of peptides with
low affinity for MHC-II molecules.
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EXPRESSION OF HLA-DR AND DM IN AUTOIMMUNITY AFFECTED
TISSUE
In organs affected by autoimmune diseases, cell targets of the tissue
damage often overexpress MHC-I and ectopically express MHC-
II molecules (59–64). This MHC expression is clearly related to
the maintenance or even the induction of self-reactive responses,
although the mechanisms involved are not known.
The importance of this expression in the pathology may vary
in the different tissues. There is very high expression of MHC-II in
autoimmune TFC, whereas class II expression in pancreatic islets
in diabetes is not so clear, despite the stronger association to HLA-
DR and -DQ alleles with T1D compared to thyroid autoimmunity
(65). HLA-DM is also expressed by autoimmune TFC, although at
lower levels than in conventional APCs (66). In the absence of DM
or if DM is insufficient, high affinity peptides may be outcompeted
by low-affinity peptides.
In addition, characteristics of particular alleles associated with
disease may also influence the autoimmune processes. In the
mouse, it is well known that H-2 I-Ag7 of the NOD mouse is a weak
peptide binder with a highly specific binding motif (67). In human,
the HLA-DR3 allele, associated with a wide range of autoimmune
diseases, has low affinity for CLIP (68). Thus, DR3 may not so
strictly require DM to ensure peptide presentation, avoiding effi-
cient peptide selection and allowing the binding of low-stability
peptides (69). HLA-DQ2, of the “autoimmune” HLA-DR3-DQ2
haplotype, associated with susceptibility to T1D and celiac disease,
also interacts poorly with DM (69, 70). DQ2/DQ8 heterozygous
individuals, highly susceptible to T1D, can form transdimers HLA-
DQ2α/DQ8β, capable of presenting different peptide repertoires
than their cis counterparts (71). It is not known whether trans-
dimer formation in the thymus is as efficient if at all, as it is in the
affected tissues.
UNIQUE T-CELL RECOGNITION OF TISSUE-DERIVED ANTIGENS
It has been reported that peptides from antigens expressed in tis-
sues can be presented by local APC activating self-reactive T cells.
Evidence comes from studies that show that APCs stimulate a sub-
set of T cells only when they are loaded with soluble peptide but
not with the whole protein (72). These so-called type B T cells rec-
ognize pMHC complexes that are different from those generated
when peptide is derived from intracellular processing of native
proteins. One reasonable explanation is that peptides can bind
MHC-II molecules on plasma membrane and also in recycling
vesicles, avoiding the effects of HLA-DM, so less-stable complexes
are available for presentation. Moreover, register shifting of pep-
tides at the binding groove might be relevant since loading of
exogenous peptide could lead to different conformations. Such T
cells have been reported to infiltrate islets of pre-diabetic NOD
mice (73, 74) and to escape from tolerance in EAE (75).
CONCLUDING REMARKS
One of the clues to autoimmune processes may lay in the differ-
ences of the peptide repertoire associated to MHC-II molecules
between thymus and the target tissue. Tissue-specific conditions,
including proteolysis, PTMs of proteins and high expression
of target antigens, together with the specific properties of the
disease-associated alleles, may generate an in situ repertoire with
enough differences from the repertoire in thymus to activate a
good number of otherwise low-affinity auto-reactive T cells. See
Figure 1.
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